Baseline characteristics of study cohort by initial use of aromatase inhibitor (AI) or tamoxifen (TAM).

NOTE: Pharmacy data through December 31, 2013; Missing data for entire cohort: menopausal status (n = 9), BMI (n = 28), smoking (n = 13), alcohol (n = 552), vitamin supplements (n = 37).1 Logistic regression adjusted for age at breast cancer diagnosis as a continuous variable.2 Median (overall) = 3.10 g/day, median (postmenopausal women) = 2.90 g/day.3 Osteoporosis defined by ICD-9 code (733.00–733.09) or any prior bisphosphonate prescription.4 Major fracture includes fracture of spine, humerus, wrist, or hip.Baseline characteristics of study cohort by initial use of aromatase inhibitor (AI) or tamoxifen (TAM).